The thyroid hormone receptor (TR) is a suppressor of rasmediated responses. To characterize the receptor domains involved in this function, we analyzed a panel of TRb1 mutants for their ability to interfere with ras-driven cyclin D1 activation, formation of transformation foci and tumor growth in nude mice. Our results show that the domains and mechanisms responsible for the anti-transforming and anti-tumorigenic actions of the receptor are divergent from those operating in classical T3-dependent transcriptional activation. TRb1 mutants that do not bind coactivators and do not transactivate retained the capacity of suppressing cellular transformation and tumor growth, whereas selective mutations in the hinge region affecting corepressors recruitment abolished these actions, while preserving ligand-dependent transcription. There was a strict parallelism between anti-transforming activity of the various mutants and their ability to antagonize cyclin D1 stimulation by ras, indicating that transrepression mechanisms may have an important function in suppression of the transforming effects of the oncogene by TRb1. The inhibitory action of T3 on transformation was further enhanced after over-expression of corepressors, while corepressor depletion by means of small-interference RNA reversed significantly hormonal action. This shows an important functional role of endogenous corepressors in suppression of ras-mediated transformation and tumorigenesis by TRb1
Introduction
Members of the ras family encode small GTP-binding proteins that have an important function in normal and malignant cell growth. Oncogenic mutations of Ras result in a constitutively active protein that can induce cellular transformation and are present in at least 30% of human tumors (Bos, 1989; Lowy and Willumsen, 1993) . The mitogen-activated protein kinase (MAPK) signaling pathway has an essential function in Rasinduced transformation (Campbell et al., 1998) and cyclin D1 is one of the main targets for the proliferative and transforming effects of ras (Filmus et al., 1994; Liu et al., 1995; Robles et al., 1998) .
The actions of the thyroid hormone triiodothyronine (T3) are initiated by binding to nuclear receptors (thyroid hormone receptors, TRs), the cellular counterparts of the v-erbA oncogene (Flamant et al., 2006) . TRs are encoded by two genes, a and b, which give rise to different receptor isoforms (Yen, 2001) , and display a modular structure with several regions: an N-terminal region (A/B), a conserved DNA-binding domain or region C, a hinge region D that contains residues essential for interaction with corepressors and a conserved E region that contains the ligand-binding domain (LBD) (Aranda and Pascual, 2001) .
TRs normally act by binding to DNA-response elements (TREs), generally as heterodimers with the retinoid X receptor. Unliganded TRs associate with corepressors such as nuclear receptor corepressor (NCoR) or silencing mediator of retinoic and thyroid receptor (SMRT) that belong to complexes that contain histone deacetylases and cause chromatin compactation (Lazar, 2003; Privalsky, 2004) . Ligand binding allows the release of corepressors and the recruitment of coactivators responsible for chromatin decompactation and transcriptional stimulation.
Nuclear receptors can also repress expression of genes that do not contain a hormone-response element through interference with the activity of other transcription factors and signaling pathways, a mechanism generally referred to as 'transcriptional cross-talk'. Thus, some nuclear receptors can transrepress the activity of target gene promoters that carry AP-1, CRE (cAMP-response element) or NF-kB sites (Pfahl, 1993; Mendez-Pertuz et al., 2003; Pascual and Glass, 2006; De Bosscher et al., 2008) . The receptors do not bind to these elements 'in vitro', but 'in vivo' the liganded receptors can be tethered to the promoter through protein-protein interactions (Rogatsky et al., 2001; Mendez-Pertuz et al., 2003) .
We have previously shown that TRs can inhibit ras-induced cyclin D1 transcription by antagonizing the Ras/MAPK signaling pathway through a CRE present in the proximal promoter. Furthermore, TRs block fibroblast transformation by oncogenic ras and act as suppressors of tumor formation by the oncogene in nude mice (Garcia-Silva and Aranda, 2004) . These results show the existence of a transcriptional cross-talk between TRs and the ras oncogene, which influences relevant processes such as cell proliferation, transformation or tumorigenesis.
Reduced expression as well as somatic mutations in TRb1 are found at high frequency in human hepatocellular carcinoma (Chan and Privalsky, 2006) , which frequently presents ras-activation (Ito et al., 1998) . Furthermore, we have recently shown that this receptor acts as a suppressor of invasiveness and metastasis formation by hepatocarcinoma cells (Martı´nez-Iglesias et al., 2009a, b) , suggesting that it could represent a potential therapeutic target in cancer (Aranda et al., 2009) . Recently, it has been shown that TRs could function as tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma (Zhu et al., 2010) . In this work, we have examined the TRb1 domains involved in the antagonism of ras-induced transcription in hepatocarcinoma HepG2 cells and in the anti-transforming and anti-tumorigenic actions of the receptor in NIH-3T3 fibroblasts. Our results indicate that hinge residues involved in corepressors binding are required for these actions. A functional role of the corepressors SMRT and NCoR in the receptor antitransforming effects is shown by over-expression and knock-down experiments. These results indicate that transrepression could have an important function in the antagonism of the transforming effects of the ras oncogene by the TR.
Results
TRb1 antagonizes ras-mediated stimulation of cyclin D1 in human hepatocarcinoma cells As proliferative responses to ras appear to depend on induction of cyclin D1, the levels of this protein were determined in hepatocarcinoma HepG2 cells transiently expressing Ha-ras val12 and/or TRb1. Ras increased cyclin D1 levels and T3 antagonized this response significantly when cells coexpressed Ha-ras val12 and the receptor, while Ras levels were not affected ( Figure 1a ). In addition, Ha-ras val12 stimulated activity of a reporter plasmid containing the 5 0 -flanking region of the cyclin D1 gene, and T3 strongly antagonized both basal promoter activity and the response to the oncogene in TRb1-expressing cells (Figure 1b ).
TRb1 domains involved in transrepression of the cyclin D1 promoter
To analyze the TRb domains responsible for the antagonism of ras-induced transcription, we examined the effect of mutations in different receptor domains on cyclin D1 promoter activity. T3-dependent transcription requires the recruitment of coactivators. Hormone binding induces the repositioning of the C-terminal helix 12 (H12) of the LBD that together with residues in H3, 4 and 5 forms a hydrophobic groove that accommodates the coactivator receptor interacting domain (Feng et al., 1998) . E457 in H12 and K288 in H3 of TRb1 contact directly with the coactivator and form a charge clamp that stabilizes binding. Accordingly, mutations in these residues render receptors with impaired ability to recruit coactivators such as the p160 coactivator ACTR (Figure 2a ) and to mediate T3-dependent transcriptional activation (Figure 2b ). In contrast, the K288I mutant was at least as active as the native receptor to antagonize the activation of the cyclin D1 promoter by , and the H12 mutant still presented a significant repressor activity (Figure 2d ). The H12 and H3 mutants were expressed at levels comparable with those of the native receptor and neither the native receptor nor the coactivator mutants reduced Ras levels (Figure 2c ). These mutants were also able to antagonize induction of cyclin D1 protein by Ras (Supplementary Figure 1) . Therefore, association of TRb1 with classical coactivators does not appear to be essential for inhibition of Ras transcriptional activity.
The role of corepressors on transrepression was assessed with the use of TRb1 mutants in the hinge Antagonism of Ras responses by TRb1 S García-Silva et al domain. A triple-point mutation (AHT-GGA) in the CoR box located in H1 blocks interaction with SMRT and NCoR (Ho¨rlein et al., 1995; Perissi et al., 1999; Marimuthu et al., 2002) and appears to affect the overall structure of the LBD (Pissios et al., 2000) . In addition, the P214R mutant in a residue preceding H1 was reported to lack silencing activity without altering LBD stability (Tagami et al., 1997; Pissios et al., 2000) . These mutations interfered with SMRT interaction in pull-down assays (Figures 3a and b) and were not able to suppress ligand-independent activity on a TRE, while supporting significant T3-dependent transactivation (Figure 3d ). Although these mutants were expressed at similar levels as the wild-type receptor and did not alter Ha-ras val12 levels (Figure 3e ), they were unable to repress cyclin D1 promoter induction by the oncogene (Figure 3f ), suggesting that binding of corepressors to TRb1 is required for transcriptional antagonism. We also analyzed the effect of mutation R243W that does not affect SMRT or NCoR binding to the unoccupied receptor, but inhibits corepressor release in the presence of T3 (Safer et al., 1998; Figures 3a and b) , whereas supporting coactivator recruitment (Figure 3c ). This mutant had silencing activity in the absence of ligand and reduced TRE-dependent transactivation possibly because of the abnormal corepressor release (Figure 3d ), but in contrast with other hinge mutants was able to support significant transrepression of the cyclin D1 promoter by T3 (Figure 3f ). In addition, expression of the R243W mutant reduced cyclin D1 protein levels in cells expressing , while the AHT mutant had little effect (Supplementary Figure 2) .
Residues in the hinge region are required for repression of ATF-2 transcriptional activity by TRb1 We have shown that T3 blocks cyclin D1 activation by Ras by antagonizing the Ras/MAPK signaling pathway (Garcia-Silva and Aranda, 2004) . The MAPK extra- 
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S García-Silva et al cellular signal-regulated kinase 1/2 activates downstream kinases such as Rsk or Msk (Anjum and Blenis, 2008) , which then phosphorylate b-Zip transcription factors of the CREB/ATF family that bind CRE motifs (Xing et al., 1996) . In agreement with this, mutation of CRE or Sp1 sites in the cyclin D1 promoter reduced induction by Ha-ras val12 and combined mutation of both motifs essentially abolished its effect (Figure 4a ). TRs can interact with CREB inhibiting its phosphorylation (Mendez-Pertuz et al., 2003) , and, as shown in Figure 4b , TRb1 also interacts directly with the b-Zip factor ATF-2 (activation transcription factor-2) in pulldown assays. In addition, cotransfection of a dominantnegative ATF-2 blocked the promoter response to Ha-ras val12 (Figure 4c) , showing the implication of CRE-binding factors. The CRE binds constitutively b-Zip factors and, accordingly, neither Ras nor TRb1 alters the abundance of the factors that bind this motif Antagonism of Ras responses by TRb1 S García-Silva et al (Figure 4d ). However, Ha-ras val12 induced transcriptional activation of ATF-2, as assessed by cotransfection of a GAL4-ATF-2 fusion with a reporter plasmid containing binding motifs for GAL4, and this activation was blocked by the native receptor in a T3-dependent manner. In contrast, the hinge TRb mutants that were unable to mediate transrepression of the cyclin D1 promoter also lost the ability of antagonizing ATF-2 activation by the oncogene (Figure 4e ).
SMRT and NCoR increase antagonism of Ras by TRb1
We have previously shown that T3 reduces cyclin D1 levels in NIH-3T3 fibroblasts transfected with Ha-ras val12 and TRb1 (Garcia-Silva and Aranda, 2004) . As shown in Figure 5a , TRb1 also antagonized ras-induced cyclin D1 promoter activation in NIH-3T3 cells, whereas the receptor mutants that do not bind corepressors were inactive. Expression of the receptors did not alter Ras levels in NIH-3T3 cells in the absence or presence of ligand (Figure 5a; Supplementary Figure 3) . To further examine the role of corepressors on transrepression, NIH-3T3 cells were transfected with expression vectors for SMRT and NCoR. Corepressor expression did not alter the levels of transfected Ras, and in the absence of receptor, SMRT reduced cyclin D1 promoter activity, whereas in the presence of the unliganded receptor, both corepressors significantly enhanced T3-dependent repression (Figure 5b) . Furthermore, the endogenous receptor that is expressed at low levels in NIH-3T3 cells was able to mediate a clear T3-dependent inhibition of promoter activity after NCoR transfection, showing increased T3 sensitivity in cells expressing high NCoR levels. Increased sensitivity was also found in HepG2 cells transfected with NCoR (Supplementary Figure 4) . Furthermore, a stronger inhibitory effect of T3 on endogenous cyclin D1 levels in NIH-3T3 cells in response to corepressor over-expression was also observed (Supplementary Figure 5) . These results suggest again that corepressors have a function in transrepression by TRb1.
Receptor domains involved in the anti-transforming activity of TRb1
We next examined the effect of TRb1 mutants on the repression of Ras-induced transformation. For this purpose, we performed foci formation assays in NIH-3T3 fibroblasts transfected with Ha-ras val12 and various TRb1 mutants. The results obtained showed a strict parallelism between repression of Ha-ras val12 -induced transcription and inhibition of transformation. The number of transformation foci was greatly reduced by T3 in fibroblasts coexpressing the oncogene and the native receptor (Figure 6a ). In contrast, the AHT and P214R receptors that do not bind corepressors were unable to mediate ligand-dependent anti-transforming effects, whereas R243W had detectable activity (Figure 6b ), indicating that the residues required for transrepression are also essential to antagonize cellular transformation by . Furthermore, the LBD mutants E457 and K288 that bind T3 but do not recruit coactivators can antagonize Ras-mediated transcription and were able to repress fibroblast transformation by . Unsurprisingly, a TRb1 mutation in the LBD (PV mutant), which produces a frameshift in H12 resulting in total loss of T3 binding (Meier et al., 1992) , was devoid of ligand-mediated anti-transforming activity (Figure 6c) , and the same occurred with v-ErbA that does not bind hormone and that in contrast with its TRa proto-oncogene was unable to antagonize foci formation by Ha-ras val12 in the presence of T3 (data not shown). 
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Functional role of SMRT and NCoR on the antagonism of Ras-induced transformation by TRb1
As increased corepressor levels enhance T3-dependent transrepression of the cyclin D1 promoter, the influence of SMRT and NCoR over-expression on NIH-3T3 transformation was also examined. The anti-transforming effects of T3 became more notorious after cotransfection of TRb1 with expression vectors for SMRT (Figure 7a ) or NCoR (Figure 7b ), suggesting again that these corepressors participate in the inhibition of the responses to Ha-ras val12
. Next, short-interfering RNA (siRNA) was used to directly address whether endogenous SMRT and NCoR have a functional role in the antitransforming ability of TRb1. For this purpose, NIH-3T3 cells were cotransfected with Ha-ras val12 , TRb1 and control, SMRT or NCoR siRNAs. Corepressor protein and mRNA levels were reduced by the corresponding siRNAs (Figures 8a and b, respectively) , without altering TRb1 levels (Figure 8a) , and transformation by Ha-ras val12 was enhanced in NCoR-and SMRTdepleted cells, in comparison with that found with the cells transfected with the control siRNA, the increase in transformation being stronger in NCoR-depleted cells (Figure 8c ). In addition, siRNAs for NCoR, and to a lesser extent SMRT, alleviated T3-dependent inhibition of foci formation, showing that these coregulators are essential for inhibition of cellular transformation by this hormone. 
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The AHT corepressor mutant fails to impair tumor growth in nude mice To analyze the TRb1 domains responsible for the repression of tumor formation by Ras, NIH-3T3 cells expressing Ha-ras val12 (Garcia-Silva and Aranda, 2004) were transfected in a stable manner with wild-type TRb1 or with the AHT and E457Q mutants. These fibroblasts, which express at similar levels the oncoprotein and the various receptors (Figure 9a ), were injected into the flanks of immunodeficient mice, and tumor growth was followed for 30 days. Tumor formation was strongly repressed in mice injected with fibroblasts coexpressing Ha-ras val12 in combination with either the native receptor or the E457 mutant, whereas tumor development was not inhibited by the AHT mutant ( Figure 9b ). These results show the importance of corepressors and the dispensability of coactivators recruitment not only for the anti-transforming effects of the receptor, but also to inhibit tumor formation in mice.
Discussion
We have previously shown that TRb1 is a strong suppressor of the actions of the ras oncogene and that repression of cyclin D1 expression by T3 appears to be an important component of the mechanism by which the hormone blocks Ras-dependent actions (Garcia-Silva and . In this work, we show that induction of cyclin D1 by Ras in hepatocarcinoma cells is dependent on the integrity of CRE and Sp1 motifs located at the proximal promoter and is antagonized by T3 in TRb1-expressing cells. The CRE binds factors of the CREB/ATF family, and the receptor does not alter the abundance of the factors that bind this motif, but attenuates their transcriptional activity (Garcia-Silva and . In agreement with this, we now show that ATF-2 transcriptional activity is markedly enhanced upon expression of Ha-ras val12 and is repressed by T3 in hepatocarcinoma cells. TRs can antagonize CREmediated transcription without binding to this motif by a direct interaction of the receptor with the b-Zip factor CREB (Mendez-Pertuz et al., 2003) and we now observe that the receptors can also interact with ATF-2. Whereas the liganded TRb1 represses cyclin D1 expression, it has been reported that repression via the CRE is lost in the TRb1 mutant PV (Furumoto et al., 2005) . The PV mutation was identified in a patient with thyroid hormone resistance syndrome and is tumorigenic in mice (Suzuki et al., 2002) . It has been postulated that the lack of T3-dependent cyclin D1 repression by the PV mutant results in constitutive activation of cyclin D1 contributing to its tumorigenic effects (Furumoto et al., 2005) . 
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We have previously reported that repression of cyclin D1 expression appears to have a function in the antitransforming effect of TR in NIH-3T3 fibroblasts (Garcia-Silva and Aranda, 2004) . Our present data show that whereas the PV mutant that has lost T3 binding was unable to repress transformation in response to the hormone, the LBD mutants K288I and E457Q preserved T3-dependent anti-transforming capacity, as well as their ability to repress cyclin D1 activation by Ras. These results indicate the dispensability of the charge clamp between H3 and H12 for inhibition of Ras responses, although the clamp is crucial for coactivators recruitment and ligand-dependent transactivation, and predict that these mutations would not be tumorigenic in mice or when present in patients. Indeed, the E457Q mutant was able to antagonize tumor formation by Ras-transformed fibroblasts in mice as strongly as the native receptor. Furthermore, the finding that the interaction of TRb1 with classical coactivators appears to be dispensable to an important extent for the antagonism of Ras-mediated responses by TRb1 supports a model wherein receptormediated antagonism is not intrinsically linked to activation and that both can be separated mechanistically. However, at present we cannot dismiss the possibility that TRb1 could use a different activation domain and/or non-classical coactivators to drive expression of factors that could affect cyclin D1 expression or tumorigenesis.
Our results show an important role for the hinge domain on TRb1 antagonism of Ras-induced transcription, transformation and tumorigenesis. Mutation AHT in the CoR box abolished these receptor actions, suggesting that corepressors could be involved. However, in addition to been required for corepressor binding, the CoR box has also a central function in stabilizing the global structure of the LBD (Pissios et al., 2000) and, therefore, the effects of AHT mutation cannot be unambiguously attributed to deficient corepressors recruitment. Therefore, we tested the effect of P214R mutation that abolishes corepressor binding (Tagami et al., 1997) without affecting overall receptor structure or stability (Pissios et al., 2000) . This mutation is homologous to that present in a v-erbA transformation-deficient mutant (td359) that lacks silencing activity (Damm et al., 1987) . The results obtained with this mutant again favored the hypothesis that binding of corepressors to TRb1 is a requisite for the antitransforming effects of the receptor and for its ability to antagonize Ras-mediated transcription in a T3-dependent manner. The finding that both corepressor mutants were still able to mediate TRE-dependent transcription again showed that Ras antagonism could be mechanistically separated from classical liganddependent transactivation. Contrary to AHT and P214R mutants, the R243W mutant was able to antagonize Ras-mediated responses. Therefore, in contrast with the prominent role of corepressor binding to the unliganded receptor, T3-dependent release does not appear to be required to inhibit transformation or to antagonize stimulation of cyclin D1 promoter activity by Ras. It is still unclear how corepressors that are released in response to hormone might be required for T3-dependent Ras antagonism. Furthermore, the effect of the receptor mutants on transformation parallel those on cyclin D1 expression, as the coactivator mutants and the R243 mutant were still able to reduce as strongly as the native receptor cyclin D1 promoter activity and the levels of cyclin D1 protein in cells, while the AHT corepressor mutant was ineffective. On the other hand, Antagonism of Ras responses by TRb1 S García-Silva et al the oncogenic TR mutants such as v-erbA or PV that act as dominant negatives blocking the anti-proliferative effects of the wild-type receptors do not suppress Ras function, although they bind corepressors constitutively, indicating that ligand binding is also required for this receptor action.
A functional role for corepressors on inhibition of cyclin D1 induction by Ras was also suggested by experiments in which SMRT and NCoR were overexpressed. There is evidence that corepressors could be involved in T3-dependent negative regulation of gene expression through negative TREs and that coactivators and corepressors could have a reversed role in this context, as corepressors can activate rather than suppress basal transcription of genes that are negatively regulated by T3 (Tagami et al., 1997; Berghagen et al., 2002) . In addition, it has been recently shown that NCoR and SMRT are required for full estrogen receptor transcriptional activity (Peterson et al., 2007) , indicating the complexity of the role of coregulators on nuclear receptor action. It is then conceivable that NCoR and SMRT could function as TR coactivators in the setting of Ras-transformed cells. Interestingly, we found that coexpression of corepressors with TRb1 enhanced T3 antagonism of cylin D1 activation by ras. This was particularly relevant in the case of NCoR, as T3 was able to repress induction of promoter activity by the oncogene even in the absence of exogenously transfected receptor. Corepressors also augmented the inhibitory effect of T3 on transformation foci by Ras, reinforcing the hypothesis that they are involved in the antagonism.
The relevant role of endogenous SMRT and NCoR on the anti-transforming effects of TRb1 was shown with siRNA experiments that revealed that corepressor down-regulation counteracted to a significant extent the inhibitory effect of T3 on cellular transformation. Furthermore, NCoR knock-down increased foci formation by Ras in the absence of transfected receptor, indicating that corepressors act to inhibit fibroblast transformation. These results agree with the increasing evidence that NCoR and SMRT influence cellular transformation and tumorigenesis. For instance, corepressor levels influence breast cancer progression (Peterson et al., 2007) and acquisition of tamoxifen resistance (Lavinsky et al., 1998) , the aberrant recruitment of SMRT by the oncoprotein PML-RAR is a landmark in myeloid leukemias (Hong et al., 2001) , down-regulation of SMRT can induce transformation of immortalized lymphoma cell lines (Song et al., 2005) and aberrant cytoplasmic distribution of NCoR and SMRT is a general trait of colorectal tumors (FernandezMajada et al., 2007) . Moreover, in a recent study (Furuya et al., 2009) , it has been shown that NCoR is a regulator of activation of PI3K signaling by the PV mutant TRb1 that causes development of metastastic thyroid carcinoma in mice (Suzuki et al., 2002) , and that the corepressor could be considered as a novel tumor suppressor in this model of thyroid cancer.
Therefore, our results show that the molecular mechanisms and receptor domains governing the antitransforming activity of TRb1 are clearly distinct from those leading to classical transcriptional activation that imply binding to the TRE and coactivators recruitment by the AF-2 domain. Thus, residues within the hinge domain and the corepressors SMRT and NCoR are essential to inhibit transformation, whereas p160 coactivators are dispensable. Our data demonstrating that a corepressor mutant, but not a coactivator mutant, fails to inhibit tumor formation by oncogenic Ras in nude mice further stresses this point. On the other hand, the strict parallelism found between the anti-transforming activity of TRb1 mutants and the antagonism of cyclin D1 transcription indicates that transrepression mechanisms are essential for inhibition of transformation by the receptor. This suggests that it would be possible to develop ligands that can separate TRb1 functionalities and that could have anti-transforming capacity without stimulating transcription.
Materials and methods

Transfections
For transfections, HepG2 and NIH-3T3 cells were transferred to medium containing 10% serum depleted of thyroid hormones by treatment with resin AG-1-X8 (Bio-Rad, Prat de Llobregat, Spain). Cells were transfected with the plasmids 
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S García-Silva et al indicated in the Supplementary Information by incubation with a mixture of cationic liposomes in 35 mm wells for 6 h and were then treated for 36 h in the presence and absence of 5 nM T3 in medium containing 0.1% of T3-depleted serum. Luciferase activity was determined in 10 mg of cell protein and transfection efficiency was determined by cotransfection with a renilla vector (50 ng).
Gel retardation assays
An oligonucleotide corresponding to a consensus TRE (5 0 -AGCTCAGGTCACAGGAGGTCAG-3 0 ) or the cyclin D1 CRE (5 0 -AGCTTAACAACAGTAACGTCACACGGACTA CA-3 0 ) was used in the assays. Wild-type and mutant TRs as well as retinoid X receptor (cloned in pSG5) were used for in vitro transcription and translation with TNT Quick (Promega, Alcobendas, Spain). Assays were performed with cell extracts (10 mg) or with in vitro translated receptors (1.5 ml of each receptor subunit in the presence and absence of 1 mM T3). Assays were performed as previously described (Castillo et al., 2004) .
GST pull-down assays Protein-protein interactions were performed with 5 ml of in vitro translated wild-type or mutant 35 S-TRb1 and with the fusion proteins GST-SMRT, GST-NCoR, GST-ACTR, GST-ATF-2 (kindly provided by Pedro Lazo) or with GST as a control (Castillo et al., 2004; Sanchez-Martinez et al., 2006) . Fifteen minutes before and during the binding reaction,
35
S-TRb1 mutants were incubated in the absence or presence of 1 mM T3. The bound proteins were analyzed by SDS-PAGE in a 10% polyacrylamide gel and identified by autoradiography.
Western blot analysis
Whole extracts from cells transiently transfected with expression vectors for TRb1 and/or Ha-ras Val12 (50 ng) were treated with 5 nM T3 for 36-48 h and used for immunodetection of cyclin D1, with antibody sc-718 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a 1:2000 dilution as described (Garcia-Silva and Aranda, 2004) . Transfected Ha-ras Val12 was detected with antibody sc-520 and NCoR and SMRT levels with antibodies 32582 (Upstate, Lake Placid, NY, USA) and PAI-842 (Affinity BioReagents, Rockford, IL, USA), respectively. b-actin (SC-1615) or total extracellular signal-regulated kinase 2 (SC-154) were used as loading controls.
Foci formation assays NIH3T3 fibroblasts were plated in 90 mm dishes and transfected with calcium phosphate with 100 ng of Ha-ras Val12 and 4 mg of expression vectors for wild-type or mutant TRb1 (Garcia-Silva and Aranda, 2004) . In some experiments, cells were also transfected with 4 mg of expression vectors for SMRT and NCoR. Empty vectors were used to equal the amount of plasmid. Cultures were fed with thyroid hormonedepleted medium in the presence and absence of 5 or 0.2 nM T3. For siRNA experiments, the cells were transfected with 400 ng of Ha-ras Val12 , 0.5 mg of TRb1 and 33 nM siRNAs using lipofectamine2000 (Invitrogen, Prat de Llobregat, Spain). siRNAs for NCoR (M-058556), SMRT (M-045364) and Non-target control (M-001210) were from Dharmacon (Lafayette, CO, USA). At 14-16 days after transfection, foci were stained with Giemsa and counted. Data are expressed as the percentage of the foci obtained in Ha-ras Val12 transfected cells that normally ranged between 75 and 120.
Real-time PCR Total RNA was extracted 2 and 5 days after transfection with siRNAs using Tri Reagent (Sigma, St Louis, MO, USA), and mRNA levels were analyzed by quantitative reverse transcription-PCR. RT was performed with 2 mg of RNA following specifications of SuperScript First-Strand Synthesis System (Invitrogen Life Technologies, Carlsbad, CA, USA). PCRs reactions were performed in an Mx3005P thermocycler (Stratagene, Madrid, Spain) and detected with Sybr Green using the following primers: 5 0 -GCTGCAGGAGAGGTT TATCG-3 0 (forward) and 5 0 -CCTGCATCTGCTGTGAGG TA-3 0 (reverse) for NCoR, and 5 0 -TGTCACCTCAGCCAG CATAG-3 0 (forward) and 5-CGCCGTAAGTAGTCCTCC TG-3 (reverse) for SMRT. Values obtained were corrected by L19 expression and results were analyzed by the C T comparative method (DDC T ).
Tumorigenesis in nude mice NIH-3T3 fibroblasts expressing Ha-Ras val12 (Garcia-Silva and Aranda, 2004) were transfected with 1 mg of empty vector, pLPCX-TRb1 or the AHT and E457Q mutants and selected with puromycin. Pools of resistant cells were used in all cases. For tumor formation in mice (athymic nude), 10 6 cells were injected subcutaneously into each flank of five mice. Tumor appearance was followed for 30 days. Experiments were performed in compliance with European Community law 86/609/EEC and were approved by the Consejo Superior de Investigaciones Cientı´ficas committee.
